AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11875328
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (E(2)) plus progestogen
Trial: 29486338
Drug: Palmitoylethanolamide (PEA)
RxNorm normalized name: Palmitoylethanolamide
DrugBank: Palmidrol (DB14043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palmitoylethanolamide (PEA) 600 mg twice daily
Trial: 25195352
Drug: P. oleracea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P. oleracea seeds (500 mg) taken two times a day for one month
Trial: 25195352
Drug: Placebo (lactose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (lactose) capsules taken two times a day for one month
Trial: 20510551
Drug: oral methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral methadone
Trial: 16438017
Drug: Oral 10
RxNorm normalized name: Syringe Oral 10cc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 10 mg diazepam in the evening before surgery and 1.5 mg midazolam at least 15 min before surgery
Trial: 12592230
Drug: Raloxifene (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene (60 mg per day for 6 weeks)
Trial: 10100957
Drug: Daily plasmapheresis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily plasmapheresis
Trial: 10100957
Drug: Alternately daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternately daily plasmapheresis
Trial: 26791869
Drug: ch14.18-UTC (17.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ch14.18-UTC (17.5 mg/m²/day)
Trial: 26791869
Drug: ch14.18-NCI (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ch14.18-NCI (25 mg/m²/day)
Trial: 20564152
Drug: Historic control
RxNorm normalized name: typhus, historical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Historic control group (HCG) receiving the same chemotherapy regimen and irradiation at doses of 40 Gy and 30 Gy, respectively.
Trial: 16499954
Drug: Continuous treatment
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous treatment with 2 mg 17beta‐estradiol plus 1 mg norethisterone acetate (n=30)
Trial: 16499954
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg raloxifene (n=24)
Trial: 1815302
Drug: Pyridostigmine (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine (120 mg orally)
Trial: 7476342
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 tablets orally)
Trial: 30615896
Drug: Immediate prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate prescription of glasses (1.00 D less than full cycloplegic hyperopia)
Trial: 28114954
Drug: Endoscopic sinus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic sinus surgery in addition to medication
Trial: 12645641
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy only
Trial: 15476905
Drug: Olopatadine hydrochloride
RxNorm normalized name: Olopatadine Hydrochloride
DrugBank: Olopatadine (DB00768)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olopatadine hydrochloride ophthalmic solution 0.2%
Trial: 11778075
Drug: G-CSF (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (5 microg/kg subcutaneously until Day 13 after PBPCT)
Trial: 31658265
Drug: Sterile males
RxNorm normalized name: Steril-Eyes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile males produced from combining the sterile insect technique using radiation with the insect incompatible technique through Wolbachia‐induced incompatibility (SIT/IIT); approximately 100-200 sterile males released weekly in each household for 6 months.
Trial: 29397189
Drug: 342 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 342 μg IBI‐10090 dexamethasone drug delivery suspension
Trial: 29397189
Drug: 517 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 517 μg IBI‐10090 dexamethasone drug delivery suspension
Trial: 24918735
Drug: Cultured epithelial
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cultured epithelial autografts (JACE) combined with autograft and artificial dermis preparation
Trial: 31687205
Drug: Olmesartan (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan (20 mg/day)
Trial: 19513973
Drug: Acemetacin (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acemetacin (180 mg/day)
Trial: 17489767
Drug: Fibrinolytics (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinolytics (administered within six hours of first chest symptoms)
Trial: 17489767
Drug: Anticoagulants (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulants (administered after optimal time)
Trial: 10576122
Drug: Recombinant interleukin-2
RxNorm normalized name: Recombinant interleukin-2 human
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recombinant interleukin-2 (rIL-2) treatment
Trial: 8896528
Drug: Control whole
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control whole cell vaccine
Trial: 1665490
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion chemotherapy with doxorubicin and ifosfamide
Trial: 1665490
Drug: Intravenous bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus chemotherapy with doxorubicin and ifosfamide
Trial: 6342842
Drug: sotalol 320
RxNorm normalized name: sotalol 320 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sotalol 320 mg once daily
Trial: 28159671
Drug: Antibiotic checklist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic checklist intervention
Trial: 23936981
Drug: Ferrous fumarate
RxNorm normalized name: Ferrous Fumarate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous fumarate 200 mg/day
Trial: 23936981
Drug: Ferrous fumarate
RxNorm normalized name: Ferrous Fumarate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous fumarate 200 mg/day + Ascorbic acid 100 mg/day
Trial: 23936981
Drug: Ferrous fumarate
RxNorm normalized name: Ferrous Fumarate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous fumarate 200 mg/day + Ascorbic acid 500 mg/day
Trial: 19959335
Drug: Bupivacaine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (10 cc of 2.5mg/cc with 1:80.000 epinephrine)
Trial: 18260764
Drug: 15 microg
RxNorm normalized name: Tafluprost 15 microgram/mL eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 microg of vaccine per dose with MF59
Trial: 18260764
Drug: 45 microg
RxNorm normalized name: Linaclotide 145 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 microg per dose of vaccine alone
Trial: 18260764
Drug: Vaccine at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine at 15 or 7.5 microg per dose with MF59
Trial: 18260764
Drug: Vaccine at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine at 30, 15, or 7.5 microg per dose with aluminum hydroxide
Trial: 16809802
Drug: Methoxsalen (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methoxsalen (40 mg)
Trial: 16809802
Drug: Cyclosporine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (200 mg)
Trial: 14570793
Drug: Sequential Compression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential Compression Device (SCD) with thigh-high sleeves at a preset pressure of 50 mm Hg
Trial: 8627582
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg tirilazad mesylate solution orally with 200 mg ketoconazole once daily
Trial: 8627582
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg i.v. tirilazad mesylate solution with 200 mg ketoconazole once daily
Trial: 8627582
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg tirilazad mesylate solution orally
Trial: 8627582
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg i.v. tirilazad mesylate solution
Trial: 1360277
Drug: 400 mg/day
RxNorm normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/day of azidothymidine (AZT), group A
Trial: 1360277
Drug: 800 mg/day
RxNorm normalized name: RibaTab 800 mg/day Compliance Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg/day of azidothymidine (AZT), group B
Trial: 3881645
Drug: Soluble insulin
RxNorm normalized name: Soluble insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Soluble insulin at 10 U/mL
Trial: 3881645
Drug: Soluble insulin
RxNorm normalized name: Soluble insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Soluble insulin at 40 U/mL
Trial: 3881645
Drug: Soluble insulin
RxNorm normalized name: Soluble insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Soluble insulin at 100 U/mL
Trial: 3881645
Drug: Bolus SC
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus SC injection of soluble insulin at 40 U/mL
Trial: 20483887
Drug: Quarter dose
RxNorm normalized name: Quarter Mate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quarter dose botulinum toxin A
Trial: 20483887
Drug: Half dose
RxNorm normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half dose botulinum toxin A
Trial: 20483887
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline injections (Control)
Trial: 10214018
Drug: Topical prostaglandin
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical prostaglandin E1 (PGE1) 8 micrograms.g‐1
Trial: 10214018
Drug: Topical prostaglandin
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical prostaglandin E1 (PGE1) 4 micrograms.g‐1
Trial: 10214018
Drug: Topical prostaglandin
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical prostaglandin E1 (PGE1) 0 microgram.g‐1, 2 micrograms.g‐1, 4 micrograms.g‐1, and 8 micrograms.g‐1
Trial: 526397
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of labetalol
Trial: 526397
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of labetalol
Trial: 17309377
Drug: FSN intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FSN intervention (needles inserted and swayed in the subcutaneous layer 200 times in 2 minutes)
Trial: 15036490
Drug: peroral estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: peroral estradiol valerate 2 mg/day
Trial: 15036490
Drug: transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: transdermal estradiol gel containing 1 mg estradiol/day
Trial: 11804247
Drug: Trihydroxyethylrutosides (HR)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trihydroxyethylrutosides (HR) 300 mg, 2 tablets daily for 2 weeks
Trial: 11804247
Drug: Trihydroxyethylrutosides (HR)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trihydroxyethylrutosides (HR) 300 mg, continued for another 2 weeks if symptoms persisted
Trial: 2820619
Drug: Cyclic combination
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic combination of 2 mg oestradiol valerate (21 d) and 1 mg cyproterone acetate (11 d)
Trial: 29540584
Drug: CBD 5
RxNorm normalized name: MENTHOL 0.06 g in 1 g TOPICAL GEL [Sombra Plus CBD 500MG Cool Therapy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD 5 mg/kg/d
Trial: 29540584
Drug: CBD 10
RxNorm normalized name: MENTHOL 0.06 g in 1 g TOPICAL GEL [SOMBRA PLUS CBD 1000MG COOL THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD 10 mg/kg/d
Trial: 29540584
Drug: CBD 20
RxNorm normalized name: MENTHOL 0.06 g in 1 g TOPICAL GEL [SOMBRA PLUS CBD 2000MG COOL THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD 20 mg/kg/d
Trial: 22035956
Drug: Oral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutritional supplements as needed until three months after hip fracture surgery
Trial: 20142336
Drug: 2-injection technique
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-injection technique (group 1, n = 56)
Trial: 20142336
Drug: 4-injection technique
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-injection technique (group 2, n = 58)
Trial: 17432681
Drug: Xuezhikang (XZK)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuezhikang (XZK) plus standard CHF treatment (angiotensin converting enzyme inhibitor, beta‐receptor inhibitor, digoxin, diuretic) for six months
Trial: 17432681
Drug: Standard CHF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard CHF treatment (angiotensin converting enzyme inhibitor, beta‐receptor inhibitor, digoxin, diuretic)
Trial: 16398773
Drug: 400 microg
RxNorm normalized name: Fentanyl 400 microgram buccal film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 microg oral misoprostol
Trial: 7743295
Drug: Curosurf (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curosurf (200 mg/kg initial dose; up to two additional doses of 100 mg/kg after 12 and 24 hours if needed)
Trial: 7743295
Drug: Survanta (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Survanta (100 mg/kg initial dose; up to three additional doses of 100 mg/kg between six and 48 hours if needed)
Trial: 28842733
Drug: Low-dose KHCO3
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose KHCO3 (1 mmol/kg/day)
Trial: 28842733
Drug: High-dose KHCO3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose KHCO3 (1.5 mmol/kg/day)
Trial: 24086581
Drug: Therapeutic education
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic education on antibiotic use delivered by a pharmacist (30-minute face-to-face session).
Trial: 24086581
Drug: Therapeutic education
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic education on antibiotic use (intervention group).
Trial: 21846460
Drug: FRP combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FRP combined with metronidazole and amoxicillin
Trial: 21846460
Drug: Systemic use
RxNorm normalized name: Psoralens for systemic use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic use of metronidazole and amoxicillin or doxycycline
Trial: 19125434
Drug: Probiotic treatment
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic treatment in severe pancreatitis
Trial: 17596104
Drug: Bevirimat (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevirimat (25 mg, 50 mg, 75 mg with 150 mg loading dose, 100 mg, 150 mg, 200 mg)
Trial: 12964231
Drug: Emla (lignocaine/prilocaine)
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Emla (lignocaine/prilocaine) anaesthetic cream
Trial: 7509495
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg risperidone
Trial: 7509495
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg risperidone
Trial: 7509495
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg clozapine
Trial: 1970907
Drug: Pseudoephedrine 60
RxNorm normalized name: CTM 4/PSEUDOEPHEDRINE 60MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pseudoephedrine 60 mg
Trial: 8721493
Drug: Saline injections
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline injections (control)
Trial: 28368334
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein and fiber (HPHF; HP = 25 g, HF = 8 g)
Trial: 28368334
Drug: Normal protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal protein and high fiber (NPHF; NP = 12.5 g, HF = 8 g)
Trial: 28368334
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein and normal fiber (HPNF; HP = 25 g, NF = 2 g)
Trial: 28368334
Drug: Normal protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal protein and fiber (NPNF; NP = 12.5 g, NF = 2 g)
Trial: 16446323
Drug: BAY 43‐9006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 43‐9006 (sorafenib) 400 mg orally twice daily
Trial: 7994792
Drug: Intravesical instillation
RxNorm normalized name: ADSTILADRIN Suspension for Intravesical Instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical instillation of Adriamycin (ADM) plus verapamil (VR) (30 mg/24 ml physiological saline + 15 mg/6 ml saline)
Trial: 7994792
Drug: Intravesical instillation
RxNorm normalized name: ADSTILADRIN Suspension for Intravesical Instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical instillation of Adriamycin (ADM) alone (30 mg/30 ml physiological saline)
Trial: 2838926
Drug: 5000 IU
RxNorm normalized name: D 5000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5000 IU conventional heparin
Trial: 2838926
Drug: 5000 anti‐Xa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5000 anti‐Xa U of low molecular weight heparin (Fragmin)
Trial: 26165736
Drug: Intravenous proton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous proton pump inhibitor (PPI) before ESD
Trial: 26165736
Drug: No intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intravenous proton pump inhibitor (PPI) before ESD
Trial: 21943845
Drug: Early antiretroviral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early antiretroviral treatment (ART) initiated before 12 weeks
Trial: 3310563
Drug: Maximum activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximum activity of aspartate aminotransferase (ASAT), analyzed once daily for 3 days
Trial: 31954063
Drug: Oral stimulation
RxNorm normalized name: follicle stimulating hormone / luteinizing hormone Injection [Menopur]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral stimulation
Trial: 26846612
Drug: Cognitive-behavioural therapy-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural therapy-based psychoeducation
Trial: 23909846
Drug: Topical indometacin
RxNorm normalized name: indometacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical indometacin applied immediately post-PDT
Trial: 23909846
Drug: Intradermal injection
RxNorm normalized name: Dryvax Intradermal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal injection of l-NAME into 5-ALA-PDT-treated sites
Trial: 16552410
Drug: Dietary supplement
RxNorm normalized name: dietary supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplement with 40 mg/day ephedra alkaloids and 100 mg/day caffeine
Trial: 27227930
Drug: Control supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control supplement
Trial: 16552410
Drug: Dietary supplement
RxNorm normalized name: dietary supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplement with ephedra and caffeine
Trial: 14559886
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (ondansetron and dexamethasone on day 1; dexamethasone on days 2 to 4)
Trial: 1421625
Drug: Ofloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (200 mg b.i.d. for 10 days)
Trial: 1421625
Drug: Fleroxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin (400 mg s.i.d. for 7 days)
Trial: 1421625
Drug: Fleroxacin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin (600 mg s.i.d. for 7 days)
Trial: 24104875
Drug: Doxycycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (100 mg b.i.d. for 7 days)
Trial: 1421625
Drug: Ofloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (200 mg single dose)
Trial: 30089602
Drug: Erlotinib 150
RxNorm normalized name: erlotinib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg oral daily plus 500 mg intramuscular fulvestrant on day 1, 15, 29 and every 28 days thereafter
Trial: 30089602
Drug: Erlotinib alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib alone 150 mg oral daily
Trial: 30089602
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (fulvestrant + erlotinib) in EGFR wild type patients
Trial: 26727076
Drug: NNC0195‐0092 (0.02,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NNC0195‐0092 (0.02, 0.04, 0.08, and 0.12 mg/kg)